Nurix Therapeutics, Inc. NRIX 深 沪
等待开盘 04-02 09:30:00 美东时间
15.48
-0.020
-0.13%
华盛通- 最 高16.10
- 今 开15.57
- 成交量 90.89万股
- 最 低 15.29
- 昨 收 15.50
- 总市值 16.01亿
- 52周最高 22.4999
- 市盈率 静 --
- 换手率 0.88%
- 52周最低 8.195
- 委 比 -35.44%
- 总股本 1.03亿
- 历史最高 52.38
- 量 比 0.63
- 振 幅 5.23%
- 历史最低 4.22
- 每 手 1
- 风险率 3.37%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多美股大行评级 | 潜在涨幅499.25%！Cabaletta Bio获Guggenheim升目标价至16美元，维持"买入"评级
今日重点评级关注：Guggenheim：维持Cabaletta Bio"买入"评级，目标价从15美元升至16美元；HC Wainwright & Co.：维持Palvella Therapeutics"买入"评级，目标价从255美元升至270美元
03-25 10:31
HC Wainwright & Co. Reiterates Buy on Nurix Therapeutics, Maintains $32 Price Target
HC Wainwright & Co. analyst Robert Burns reiterates Nurix Therapeutics (NASDAQ:NRIX) with a Buy and maintains $32 price target.
03-24 18:55
美股大行评级 | Meta 、IBM、拉姆研究、布林克国际等获多家机构上调目标价；微软、特斯拉、ServiceNow、自动数据处理等遭多家下调评级
今日重点评级关注：Piper Sandler：上调Korro Bio评级至"超配"，目标价从11美元升至30美元；Piper Sandler：维持Nurix Therapeutics"超配"评级，目标价从32美元升至35美元
01-30 17:38
Meta Platforms To Rally More Than 71%? Here Are 10 Top Analyst Forecasts For Thursday
Top Wall Street analysts changed their outlook on these top names. For a comple...
01-29 20:47
Needham Reiterates Buy on Nurix Therapeutics, Maintains $26 Price Target
Needham analyst Gil Blum reiterates Nurix Therapeutics (NASDAQ:NRIX) with a Buy and maintains $26 price target.
01-29 19:25
美股大行评级 | 潜在涨幅197.4%！奥麦罗制药获HC Wainwright升目标价至40美元，维持"买入"评级
今日重点评级关注：HC Wainwright & Co.：维持奥麦罗制药"买入"评级，目标价从20美元升至40美元；HC Wainwright & Co.：维持Cullinan Therapeutics"买入"评级，目标价从26美元升至27美元
01-09 20:22
Morgan Stanley Upgrades Nurix Therapeutics to Overweight, Raises Price Target to $36
Morgan Stanley analyst Terence Flynn upgrades Nurix Therapeutics (NASDAQ:NRIX) from Equal-Weight to Overweight and raises the price target from $15 to $36.
01-08 20:10
Oppenheimer’s best small and mid-cap ideas for 2026
Oppenheimer Research released a list of its best ideas for small-caps and mid-caps in the new year. Analysts said that, absent the traditional warning signs that have historically preceded market down...
01-07 00:59
Nurix Therapeutics to Participate in the 44th Annual J.P. Morgan Healthcare Conference
Nurix Therapeutics, Inc. announced that its CEO, Arthur T. Sands, M.D., Ph.D., will present a corporate update at the 44th Annual J.P. Morgan Healthcare Conference on January 12, 2026, in San Francisco. The presentation will be available via webcast on the company's website. Nurix, focused on targeted protein degradation medicines for oncology and autoimmune diseases, has a clinical-stage pipeline including BTK degraders and CBL-B inhibitors, as ...
01-05 12:00
美股大行评级 | 潜在涨幅263.64%！Milestone Pharmaceuticals获富国银行升目标价至8美元，维持"超配"评级
今日重点评级关注：富国银行：维持Milestone Pharmaceuticals"超配"评级，目标价从4美元升至8美元；富国银行：维持Kyverna Therapeutics"超配"评级，目标价从31美元升至33美元
2025-12-17 10:46
